

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
03 February 2022 (03.02.2022)



(10) International Publication Number
WO 2022/026336 A1

(51) International Patent Classification:

C07K 16/40 (2006.01) A61P 27/00 (2006.01)
A61K 31/7088 (2006.01) A61P 17/00 (2006.01)
C12N 9/48 (2006.01) A61P 19/00 (2006.01)
A61P 37/02 (2006.01)

(21) International Application Number:

PCT/US2021/043062

(22) International Filing Date:

23 July 2021 (23.07.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/056,562 25 July 2020 (25.07.2020) US
63/171,672 07 April 2021 (07.04.2021) US

(71) Applicant: **REGENERON PHARMACEUTICALS, INC.** [US/US]; 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US).

(72) Inventors: **GELFMAN, Sahar**; 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **LIGOCKI, Ann**; 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **COPPOLA, Giovanni**; 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **BARIS, Aris**; 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **MOSCATI, Arden**; 777 Old Saw Mill River Road, Tarrytown, NY 10591 (US). **STAHL, Eli A.**; 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **KOSMICKI, Jack A.**; 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **FERREIRA, Manuel Allen Revez**; 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **ROMANO, Carmelo**; 777 Old Saw Mill River Road, Tarrytown, NY 10591 (US).

(74) Agent: **LEGAARD, Paul K.**; Stradley Ronon Stevens & Young, LLP, 30 Valley Stream Parkway, Malvern, Pennsylvania 19355-1481 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,

SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: MODULATION OF ENDOPLASMIC RETICULUM AMINOPEPTIDASE 2 (ERAP2)-MEDIATED IMMUNE RESPONSE

(57) Abstract: The present disclosure provides methods of treating subjects having an immune disorder by administering a therapeutically effective amount of an Endoplasmic Reticulum Aminopeptidase 2 (ERAP2) inhibitor to the subject, and optionally an Endoplasmic Reticulum Aminopeptidase 1 (ERAP1) agonist or inhibitor and/or an HLA-Aw19 inhibitor, and also provides methods of identifying subjects having an increased risk for developing an MHC-I-opathy.

WO 2022/026336 A1